CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.
长春高新
000661
Shenzhen Stock Exchange
Company Profile
Since from its listing, the Company, by the successful incubation of innovative projects, has primarily established its leading status in domestic genetic engineering pharmaceutics and biological vaccines fields. Holding subsidiaries of the Company: Changchun GeneScience Pharmaceuticals Co., Ltd., Changchun BCHT Biotechnology Co., Ltd. and Jilin Huakang pharmaceutical Co., Ltd. are taking the dominant positions in their own medicine subdivisions. The Company practices the development concept of “Innovation, Concentration, Generosity, Sharing”. It insists to take capital as the link and scientific innovation as the source power to adjust and optimize the management mode, build the innovative cooperation platform relying on bio-pharmaceuticals, assisted by featured real estate development and shared by parties. The Company keeps a foothold on “new mileage, new field of vision and new start” to further perfect and strengthen the five industrial plates: genetic engineering pharmaceuticals, biological vaccines, modern Chinese medicine, high-end generic drugs and gestured real estate. Focus of works on HR management of the Company relies on the building of a working environment of respecting knowledge, respecting talents and respecting personality. The concept of praising success and tolerating failure is the common sense of management and entrepreneur/innovator. The Company will expand channels and develop multiple measures to employ people according to their merits with the cultural concept of tolerance.
Full description
Changchun High-tech Industry (Group) Co., Ltd. was established by Changchun High-tech Industry Development Corporation in June 1993, with a total share capital of 137,500,000 shares at that time. On December 18, 1996, CCHT stocks were listed at Shenzhen Stock Exchange. It is among the first batch of listed companies in northeast China. Since its establishment more than 20 years ago, CCHT successfully transformed from high-tech land infrastructure construction into an enterprise group focusing on the field of medical science and technology innovation and implementing industrial investment. CCHT has adhered to the corporate culture of ‘‘innovation, concentration, generosity and sharing’’, practicing the core values of creating value for customers, creating opportunities for employees, creating benefits for shareholders and taking responsibility for the society. It has established its industrial orientation with biopharmaceutical industry as the primary and real estate industry as the supplement, has formed the development platform for three industries including genetic engineering pharmaceuticals, biological vaccines and modern traditional Chinese medicine, has realized the vigorous development pattern of ‘‘four carriages’’ including GeneScience Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘‘GenSci’’, Changchun BCHT Biotechnology Co., Ltd. (hereinafter referred to as ‘‘BCHT’’, Jilin Huakang Pharmaceutical Co., Ltd. (hereinafter referred to as ‘‘Huakang Pharmaceutical’’) and Changchun High-tech Real Estate Development Co., Ltd. (hereinafter referred to as ‘‘High-tech Real Estate’’ and has opened up a good situation of shared development and win-win cooperation.